Portage Biotech Inc. (PTGEF) 0.0950 $PTGEF
Portage's Biohaven Receives Response from FDA to its Pre-IND Meeting Request
PR Newswire - Thu Dec 18, 8:00AM CST
Biohaven filed a pre-IND meeting request with the FDA regarding lead investigational agent BHV-0223, receives written response in lieu of an in-person meeting
Portage announces further successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Tue Dec 16, 8:00AM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has further validated its platform cell penetrating peptide technology for safely delivering a potent anti-inflammatory cargo into eye tissues. Its lead compound PPL-003 showed success in two studies in rabbits. In the first study, topical eye administration of PPL-003 at the highest feasible dose was well tolerated with no abnormal clinical or pathological findings. In the second study PPL-003 demonstrated efficacy in an experimental uveitis model by significantly suppressing the cellular inflammatory response in the anterior chamber and reducing the protein content of the anterior chamber aqueous humor.. These results in rabbits clearly demonstrated at least a ten-fold safety margin and confirmed the topical anti-inflammatory activity of PPL-003 previously demonstrated in a mouse uveitis model. PPL is continuing its uveitis program working toward an IND submission in 2016.
Portage Completes Non-brokered Private Placement for a Total Proceeds of US$2,000,000
PR Newswire - Thu Oct 16, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that it has completed its non-brokered private placement raising US$2,000,000 through issuance of 20 million common shares at US$0.10 each. The Company is debt free.
Portage announces additional consultants to expedite its PPL-003 development programs
PR Newswire - Mon Oct 06, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd (PPL) has added the following consultants to its team for further development of its PPL-003 for uveitis and planning for its potential Investigational New Drug (IND) application with FDA. PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye.
Portage announces conversion of its debt into equity
PR Newswire - Mon Sep 29, 1:11PM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its three Promissory Note holders, two of whom are the directors of Portage, who advanced $ 100,000 each in July 2014 for a total of $ 300,000 opted to have their Notes and related Coupons converted into 3,500,001 restricted common shares. Notes were repayable within one year and carried 5% coupon. Both the Note and the coupon were convertible into common shares to be valued at 10% discount to the current financing at $ 0.10 per share.
Portage Announces New Consultants for its PPL-003 Development Programs
PR Newswire - Tue Sep 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd (PPL) has added two more consultants to its team for further development of its PPL-003 for uveitis. PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye.
Portage Announces Proposed Private Placement
PR Newswire - Thu Sep 11, 7:57AM CDT
Portage Biotech Inc. ("Portage" or "the Company" (OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its preclinical development activities and financial commitments to Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" .
Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2
Marketwire - Wed Sep 10, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, has successfully completed additional and definitive testing confirming COTI-2's p53-dependent mechanism of action. The additional animal experiments were requested as part of Portage Biotech Inc.'s ("Portage" due diligence related to the non-binding letter of intent to form a joint venture previously announced on February 26, 2014.
COT.VN: 0.230 (+0.005)
Portage's Biohaven granted United States patent for glutamate agents in the treatment of mental disorders
PR Newswire - Wed Aug 06, 8:00AM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder (GAD) until 2029
Portage announces successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Mon Jul 14, 8:00AM CDT
Portage Biotech Inc. ("Portage" (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes. This proprietary platform technology has been shown to efficiently deliver an active pharmacological agent or cargo into a cell without disrupting the cell membrane.
Portage's Biohaven Receives Response from FDA to its Pre-IND Meeting Request
PR Newswire - Thu Dec 18, 8:00AM CST
Biohaven filed a pre-IND meeting request with the FDA regarding lead investigational agent BHV-0223, receives written response in lieu of an in-person meeting
Portage announces further successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Tue Dec 16, 8:00AM CST
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has further validated its platform cell penetrating peptide technology for safely delivering a potent anti-inflammatory cargo into eye tissues. Its lead compound PPL-003 showed success in two studies in rabbits. In the first study, topical eye administration of PPL-003 at the highest feasible dose was well tolerated with no abnormal clinical or pathological findings. In the second study PPL-003 demonstrated efficacy in an experimental uveitis model by significantly suppressing the cellular inflammatory response in the anterior chamber and reducing the protein content of the anterior chamber aqueous humor.. These results in rabbits clearly demonstrated at least a ten-fold safety margin and confirmed the topical anti-inflammatory activity of PPL-003 previously demonstrated in a mouse uveitis model. PPL is continuing its uveitis program working toward an IND submission in 2016. Portage Completes Non-brokered Private Placement for a Total Proceeds of US$2,000,000
PR Newswire - Thu Oct 16, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that it has completed its non-brokered private placement raising US$2,000,000 through issuance of 20 million common shares at US$0.10 each. The Company is debt free. Portage announces additional consultants to expedite its PPL-003 development programs
PR Newswire - Mon Oct 06, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd (PPL) has added the following consultants to its team for further development of its PPL-003 for uveitis and planning for its potential Investigational New Drug (IND) application with FDA. PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye. Portage announces conversion of its debt into equity
PR Newswire - Mon Sep 29, 1:11PM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its three Promissory Note holders, two of whom are the directors of Portage, who advanced $ 100,000 each in July 2014 for a total of $ 300,000 opted to have their Notes and related Coupons converted into 3,500,001 restricted common shares. Notes were repayable within one year and carried 5% coupon. Both the Note and the coupon were convertible into common shares to be valued at 10% discount to the current financing at $ 0.10 per share. Portage Announces New Consultants for its PPL-003 Development Programs
PR Newswire - Tue Sep 23, 8:00AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary, Portage Pharmaceuticals Ltd (PPL) has added two more consultants to its team for further development of its PPL-003 for uveitis. PPL-003 uses a new proprietary cell permeable peptide platform technology derived from human genes to deliver its anti-inflammatory cargo into the eye. Portage Announces Proposed Private Placement
PR Newswire - Thu Sep 11, 7:57AM CDT
Portage Biotech Inc. ("Portage" or "the Company"
(OTC: PTGEF, Canadian Securities Exchange: PBT.U), announces that it intends to conduct a Private Placement to raise up to US$ 2 million for funding its preclinical development activities and financial commitments to Biohaven Pharmaceutical Holding Company Limited, ("Biohaven" . Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2
Marketwire - Wed Sep 10, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, has successfully completed additional and definitive testing confirming COTI-2's p53-dependent mechanism of action. The additional animal experiments were requested as part of Portage Biotech Inc.'s ("Portage" due diligence related to the non-binding letter of intent to form a joint venture previously announced on February 26, 2014. COT.VN: 0.230 (+0.005)
Portage's Biohaven granted United States patent for glutamate agents in the treatment of mental disorders
PR Newswire - Wed Aug 06, 8:00AM CDT
Intellectual property licensed from Yale University protects the use of certain glutamate modulating agents in the treatment of Generalized Anxiety Disorder (GAD) until 2029
Portage announces successful validation of its new proprietory cell permeable peptide platform technology
PR Newswire - Mon Jul 14, 8:00AM CDT
Portage Biotech Inc. ("Portage"
(OTCQB: PTGEF, Canadian Stock Exchange: PBT.U), is pleased to announce that its wholly owned subsidiary Portage Pharmaceuticals Ltd. (PPL) has successfully validated a new proprietary cell permeable peptide platform technology derived from human genes. This proprietary platform technology has been shown to efficiently deliver an active pharmacological agent or cargo into a cell without disrupting the cell membrane. 
